EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses’ Health Studies

被引：0
作者：
Francisco Beca
Kevin Kensler
Benjamin Glass
Stuart J. Schnitt
Rulla M. Tamimi
Andrew H. Beck
机构：
[1] Beth Israel Deaconess Cancer Center,Cancer Research Institute
[2] Beth Israel Deaconess Medical Center,Department of Pathology
[3] Harvard Medical School,Department of Epidemiology
[4] Harvard T.H. Chan School of Public Health,undefined
[5] Channing Division of Network Medicine,undefined
[6] Department of Medicine,undefined
[7] Brigham and Women’s Hospital and Harvard Medical School,undefined
来源：
Breast Cancer Research | / 19卷
关键词：
Benign breast disease; Breast Cancer; Risk; EZH2; Nurses’ Health Studies;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer
    Chen, Yun
    Zhu, Hongyan
    Luo, Yi
    Tong, Shuangmei
    Liu, Yan
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [22] Family history and risk of breast cancer: nurses’ health study
    Graham A. Colditz
    Kimberly A. Kaphingst
    Susan E. Hankinson
    Bernard Rosner
    Breast Cancer Research and Treatment, 2012, 133 : 1097 - 1104
  • [23] Family history and risk of breast cancer: nurses' health study
    Colditz, Graham A.
    Kaphingst, Kimberly A.
    Hankinson, Susan E.
    Rosner, Bernard
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1097 - 1104
  • [24] Gene expression abnormalities in histologically normal breast epithelium from patients with luminal type of breast cancer
    Pavol Zubor
    Jozef Hatok
    Petra Moricova
    Karol Kajo
    Ivana Kapustova
    Andrea Mendelova
    Peter Racay
    Jan Danko
    Molecular Biology Reports, 2015, 42 : 977 - 988
  • [25] Association of clinicopathologic characteristics and outcomes with EZH2 expression in patients with breast cancer in East Azerbaijan, Iran
    Boostani, Farnaz
    Dolatkhah, Roya
    Fakhrjou, Ashraf
    Farassati, Faris
    Sanaat, Zohreh
    ONCOTARGETS AND THERAPY, 2018, 11 : 449 - 457
  • [26] EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
    Dou, Dongwei
    Ge, Xin
    Wang, Xinxing
    Xu, Xiaodong
    Zhang, Zhe
    Seng, Jingjing
    Cao, Zhang
    Gu, Yuanting
    Han, Mingli
    ONCOTARGETS AND THERAPY, 2019, 12 : 9627 - 9637
  • [27] Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis
    Wang, Xu
    Hu, Bo
    Shen, Hugang
    Zhou, Hao
    Xue, Xiaofeng
    Chen, Yan
    Chen, Shaoji
    Han, Ye
    Yuan, Bin
    Zhao, Hong
    Zhi, Qiaoming
    Kuang, Yuting
    BIOMEDICINE & PHARMACOTHERAPY, 2015, 75 : 218 - 225
  • [28] The functional role of the EZH2 gene in controlling breast cancer stem cells
    Wang, Fu-wen
    Ao, Xiang
    Fu, Shao-mei
    JOURNAL OF BUON, 2019, 24 (03): : 1060 - 1066
  • [29] EZH2 Confers Sensitivity of Breast Cancer Cells to Taxol by Attenuating p21 Expression Epigenetically
    Mu, Xin
    Chen, Minghui
    Xiao, Bo
    Yang, Bing
    Singh, Suryadeep
    Zhang, Bo
    DNA AND CELL BIOLOGY, 2019, 38 (07) : 651 - 659
  • [30] The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells
    Zeidler, M
    Varambally, S
    Cao, Q
    Chinnaiyan, AM
    Ferguson, DO
    Merajver, SD
    Kleer, CG
    NEOPLASIA, 2005, 7 (11): : 1011 - 1019
12345